aTyr Pharma, based in San Diego, focuses on developing therapies targeting tRNA synthetase biology for fibrosis and inflammation, with efzofitimod as its lead candidate for interstitial lung disease. The company went public on May 7, 2015, and has 56 employees.
Atyr Pharma (ATYR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Atyr Pharma's actual EPS was -$0.17, beating the estimate of -$0.19 per share, resulting in a 12.28% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
